• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Cellarity Appoints Biopharmaceutical Executive Ian Estepan to its Board of Directors

    12/8/21 9:00:00 AM ET
    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $AXLA alert in real time by email

    Estepan brings to Cellarity's BOD deep experience and expertise in all aspects of finance, corporate strategy, investor relations, and business development, and a dedication to directly improving patient lives through innovation in medicine

    Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointment of Ian M. Estepan to its Board of Directors. Mr. Estepan currently serves as Executive Vice President and Chief Financial Officer (CFO) of Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases. At Sarepta and as a member of Sarepta's Executive Committee, he leads finance and accounting, corporate strategy, business development, strategic alliances, investor relations, and corporate affairs, as well as diversity, equity, and inclusion.

    Mr. Estepan is a chief architect of Sarepta's global business strategy and drives the Company's annual strategic planning process. Over the course of his tenure at Sarepta he has helped secure $2.5 billion in capital to support Sarepta's growth. Additionally, he established Sarepta's corporate strategy and program management functions. Prior to joining Sarepta, Estepan managed a multi-million-dollar portfolio of biotechnology, medtech, and pharmaceutical stocks at Spectra Financial Group for 15 years.

    "Ian brings to Cellarity's Board deep experience in developing and financing corporate strategies to fund visionary biotech companies," said Stephen Berenson, Chairperson of Cellarity's Board of Directors and Managing Partner at Flagship Pioneering. "In addition, his intense focus on having a direct and lasting impact on patients' lives will help guide Cellarity in its mission to develop an entirely new approach to drug creation to deliver transformative medicines with an innately higher rate of clinical success."

    Cellarity's new drug discovery approach looks beyond an individual molecular target to understand the complex biological network of changes that drive a cell from health to disease. Cellarity combines expertise in network biology, single cell sequencing, and machine learning to understand how a cell behaves in different health and disease states and then engineers new chemical entities to broadly address the network changes to move a cell back to health. By leveraging a more complete view of the complexity of cell biology, Cellarity's drug discovery platform allows for efficient drug discovery across families of diseases related by similar cell types or cell dysfunctions and is designed to drive higher rates of clinical success.

    "By embracing the complexity of human biology, Cellarity's unique approach to drug discovery has the potential to be more efficient, more successful, and help more patients," said Estepan. "I look forward to working with the Board and leadership team to help them establish the necessary support to scale and maximize the impact Cellarity can have on patients."

    "Ian's insights and experience in developing and executing long-term strategies for global biotech companies will serve Cellarity well as we execute on our vision to fundamentally improve how drugs are created," said Fabrice Chouraqui, Ph.D., CEO of Cellarity and a CEO-Partner at Flagship Pioneering. "I look forward to working with Ian and the Board as we advance drug discovery programs in diverse therapeutic areas to meet a wide range of patient needs."

    Mr. Estepan joined Sarepta in 2015 as Senior Director, Corporate Affairs and has held several positions of increasing responsibility during his time at the Company. Prior to his appointment as CFO, he served as Sarepta's Senior Vice President, Chief of Staff and Corporate Affairs. In addition, Mr. Estepan leads diversity, equity, and inclusion at Sarepta and serves as Executive Sponsor of PRIDE (Sarepta's LGBTQ+ Employee Resource Group) and HUES (Sarepta's Black Employee Resource Group).

    Before joining Sarepta, Mr. Estepan managed a portfolio on the buyside at Spectra Financial Group, overseeing pharmaceutical, biotech, and medtech equities. Mr. Estepan received his Bachelor of Arts degree in psychology with a concentration in pre-medicine from Columbia University.

    About Cellarity

    Cellarity's mission is to bring breakthrough medicines to patients by completely redefining the way drugs are discovered. Founded by Flagship Pioneering in 2017, Cellarity is designing medicines against the cell as opposed to a single molecular target. The company has developed a unique combination of expertise across network biology, high-resolution data, and machine learning to unlock new treatment options in a vast array of disease areas. Cellarity currently has drug discovery programs underway in metabolic disease, hematology, immuno-oncology, and respiratory disease. The company has raised $123 million as part of a Series B funding round with contributions from funds and accounts managed by Blackrock, The Baupost Group, Banque Pictet on behalf of their clients, and eight other investors alongside Flagship Pioneering. For more info, visit www.cellarity.com.

    About Flagship Pioneering

    Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in more than $200 billion in aggregate value. To date, Flagship has deployed over $2.5 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 42 transformative companies, including Axcella Health (NASDAQ:AXLA), Codiak BioSciences (NASDAQ:CDAK) Denali Therapeutics (NASDAQ:DNLI), Evelo Biosciences (NASDAQ:EVLO), Foghorn Therapeutics (NASDAQ:FHTX), Indigo Ag, Kaleido Biosciences (NASDAQ:KLDO), Moderna (NASDAQ:MRNA), Omega Therapeutics (NASDAQ:OMGA), Rubius Therapeutics (NASDAQ:RUBY), Sana Biotechnology (NASDAQ:SANA), Seres Therapeutics (NASDAQ:MCRB), and Sigilon Therapeutics (NASDAQ:SGTX).

    View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005080/en/

    Get the next $AXLA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AXLA
    $CDAK
    $DNLI
    $EVLO

    CompanyDatePrice TargetRatingAnalyst
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$22.00Underweight → Equal Weight
    Barclays
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$13.00Mkt Perform
    Bernstein
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$37.00Perform → Outperform
    Oppenheimer
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$24.00Underweight → Neutral
    Analyst
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$5.00Sell
    H.C. Wainwright
    Sarepta Therapeutics Inc.
    $SRPT
    7/28/2025$10.00Equal Weight → Underweight
    Barclays
    Sarepta Therapeutics Inc.
    $SRPT
    7/25/2025Neutral → Underweight
    Analyst
    Sarepta Therapeutics Inc.
    $SRPT
    7/24/2025$7.00Sell
    Citigroup
    More analyst ratings

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Watts Ryan J. exercised 495,282 shares at a strike of $1.05 and sold $7,429,230 worth of shares (495,282 units at $15.00) (SEC Form 4)

      4 - Denali Therapeutics Inc. (0001714899) (Issuer)

      7/11/25 5:13:23 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Bishop Hans Edgar was granted 7,842 shares, increasing direct ownership by 0.13% to 5,828,955 units (SEC Form 4)

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      7/8/25 4:17:31 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Mock James M converted options into 1,453 shares and covered exercise/tax liability with 703 shares, increasing direct ownership by 5% to 16,941 units (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      7/7/25 4:59:55 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:27:16 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:24:36 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Chambers Michael Andrew bought $4,955,728 worth of shares (37,038 units at $133.80) (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      8/20/24 8:00:04 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

      Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

      7/12/24 4:40:36 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

      For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

      6/20/24 5:24:42 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

      Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

      6/5/24 4:41:31 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy

      - Company commends FDA for swift and comprehensive review of available information - Shipments to sites of care will resume imminently - Sarepta and FDA will continue dialogue on next steps in the safety labeling process and risk-mitigation approach for non-ambulatory patients Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) notified Sarepta that it may lift its voluntary pause on shipments of ELEVIDYS (delandistrogene moxeparvovec) for ambulatory patients with Duchenne. Sarepta will resume shipping ELEVIDYS to sites of care for treatment of ambulatory patients with

      7/28/25 5:09:00 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

      - Milestone earned upon reaching first enrollment target in a Phase 1/2 study of ARO-DM1 for the treatment of type 1 myotonic dystrophy Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ:SRPT). The milestone was triggered when Arrowhead reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNA interference (RNAi) therapeutic for the treatment of type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy. Arrowhead currently expects to achieve the second enrollment

      7/28/25 7:30:00 AM ET
      $ARWR
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS

      Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration (FDA) issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy (Duchenne) patient who had received ELEVIDYS (delandistrogene moxeparvovec) gene therapy. The death of this patient was deemed unrelated to treatment with ELEVIDYS. As reported yesterday by Naomi Kresge at Bloomberg News: Roche Holding AG says the recent death of a patient in Brazil who had been treated with gene therapy Elevidys for Duchenne muscular dystroph

      7/25/25 7:51:00 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sarepta Therapeutics upgraded by Barclays with a new price target

      Barclays upgraded Sarepta Therapeutics from Underweight to Equal Weight and set a new price target of $22.00

      7/29/25 10:25:29 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bernstein initiated coverage on Sarepta Therapeutics with a new price target

      Bernstein initiated coverage of Sarepta Therapeutics with a rating of Mkt Perform and set a new price target of $13.00

      7/29/25 7:40:24 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Sarepta Therapeutics from Perform to Outperform and set a new price target of $37.00

      7/29/25 7:24:05 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Sarepta Therapeutics Inc.

      SCHEDULE 13G - Sarepta Therapeutics, Inc. (0000873303) (Subject)

      7/25/25 4:08:08 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Seres Therapeutics Inc.

      8-K - Seres Therapeutics, Inc. (0001609809) (Filer)

      7/22/25 4:10:29 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Sarepta Therapeutics Inc.

      8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)

      7/21/25 7:30:13 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Leadership Updates

    Live Leadership Updates

    See more
    • Seres Therapeutics Announces Leadership Transition

      Thomas DesRosier and Marella Thorell, accomplished biopharma executives, appointed co-CEOs; Eric Shaff stepping down as CEO and will remain a Director on the Seres Board Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure additional capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced the appointment of Thomas DesRosier and Marella Thorell as co-Ch

      7/22/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ted Myles Joins Cellarity as Chief Executive Officer

      Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

      5/12/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors. "Neil and Stuart are experienced leaders with decades of deep and multifaceted understanding of the biotechnology industry," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. "We are pleased to welcome them to our Board of Directors and will leverage their strategic insights as we further advance our pipeline." Dr. Gallagher

      5/1/25 7:00:00 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Financials

    Live finance-specific insights

    See more
    • Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

      CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m. ET to discuss second quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 3641971. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours afte

      7/22/25 7:01:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label

      – After strategic review, Sarepta focuses pipeline on high-impact programs, prioritizing potentially best-in-class siRNA platform assets – Strategic restructuring includes reduced operating expenses, delivering approximately $400 million in anticipated annual cost savings, and implementing a 36% workforce reduction of approximately 500 employees – Duchenne portfolio continues to deliver stable and robust revenues, with preliminary quarterly results showing total net product revenue of $513 million for the second quarter 2025 – U.S. FDA has requested and Sarepta has agreed to include a black box warning in the ELEVIDYS label, resolving any material issues with the ambulant population i

      7/16/25 4:01:00 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

      - The Company is developing an enhanced immunosuppressive regimen in consultation with a panel of multi-disciplinary clinical experts and engaging with regulators - Shipments of ELEVIDYS for infusions in non-ambulatory patients in commercial setting are suspended until enhanced regimen is approved and in place - ENVISION study is paused while seeking a protocol amendment to incorporate additional immunosuppression - Sarepta to host investor call on June 16, 2025, at 8:00 am Eastern time Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrogene moxeparvovec-rokl), the only a

      6/15/25 1:00:00 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXLA
    $CDAK
    $DNLI
    $EVLO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/14/24 5:12:32 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/14/24 6:00:14 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

      SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

      11/13/24 10:27:59 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care